---
title: "JINLING PHARM.: The holding subsidiary has received approval for the listing of potassium sulfate"
description: "JINLING PHARM.'s subsidiary Chizhou Dongsheng Pharmaceutical Co., Ltd. has been approved by the National Medical Products Administration to list potassium sulfate, meeting domestic drug registration r"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/254414244.md"
published_at: "2025-08-25T10:27:02.000Z"
---

# JINLING PHARM.: The holding subsidiary has received approval for the listing of potassium sulfate

> JINLING PHARM.'s subsidiary Chizhou Dongsheng Pharmaceutical Co., Ltd. has been approved by the National Medical Products Administration to list potassium sulfate, meeting domestic drug registration requirements, and can be produced and sold in the domestic market. This will enrich the company's active pharmaceutical ingredient product line, but will have little impact on the company's performance in the short term

JINLING PHARM. announced that its holding subsidiary Chizhou Dongsheng Pharmaceutical Co., Ltd. recently received the "Approval Notice for the Listing Application of Chemical Raw Materials" issued by the National Medical Products Administration, approving the registration of potassium sulfate. Potassium sulfate is one of the raw materials for the concentrated solution of magnesium sodium potassium sulfate for oral use, suitable for bowel cleansing before any procedures requiring bowel preparation in adults. This approval indicates that the raw material meets domestic drug registration requirements and can be produced and sold in the domestic market, which is beneficial for enriching the company's raw material product line. However, due to the time required for production and sales, it will not have a significant impact on the company's current performance

### Related Stocks

- [000919.CN - JINLING PHARM.](https://longbridge.com/en/quote/000919.CN.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| New study finds early hormone replacement therapy reduces risk of osteoporosis and fractures for older women | A new study presented at the 2026 AAOS Annual Meeting reveals that early hormone replacement therapy (HRT) significantly | [Link](https://longbridge.com/en/news/277412093.md) |
| SSY Group's Respiratory Drug Approved for Production in China | SSY Group's Respiratory Drug Approved for Production in China | [Link](https://longbridge.com/en/news/277561555.md) |
| How can I systematically track high-win-rate wallet addresses on Polymarket? | The article discusses strategies for tracking high-win-rate wallet addresses on Polymarket, emphasizing the importance o | [Link](https://longbridge.com/en/news/277561416.md) |
| LESS NOISE, BETTER SIGNALS: HOW PHARMA CAN MEASURE IMPACT AS AI RESHAPES SEARCH | The article discusses the transformation of search in the pharmaceutical industry due to AI adoption, emphasizing the sh | [Link](https://longbridge.com/en/news/277470520.md) |
| Does RFK Jr. care that babies will needlessly die under his vaccination policies? | The article discusses the impact of Robert F. Kennedy Jr.'s vaccination policies, highlighting a resurgence of measles c | [Link](https://longbridge.com/en/news/277225914.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.